Thymosin α1

Thymosin alpha1 (Talpha1), first described and characterized by Allan Goldstein in 1972, is used worldwide for the treatment of some immunodeficiencies, malignancies, and infections. Although Talpha1 has shown a variety of effects on cells and pathways of the immune system, its central role in modulating dendritic cell (DC) function has only recently been appreciated. As DCs have the ability to sense infection and tissue stress and to translate collectively this information into an appropriate immune response, an action on DCs would predict a central role for Talpha1 in inducing different forms of immunity and tolerance. Recent results have shown that Talpha1: (a) primed DCs for antifungal Th1 resistance through Toll-like receptor (TLR)/MyD88-dependent signaling and this translated in vivo in protection against aspergillosis; (b) activated plasmacytoid DCs (pDC) via the TLR9/MyD88-dependent viral recognition, thus leading to the activation of interferon regulatory factor 7 and the promotion of the IFN-alpha/IFN-gamma-dependent effector pathway, which resulted in vivo in protection against primary murine cytomegalovirus infection; (c) induced indoleamine 2,3-dioxygenase activity in DCs, thus affecting tolerization toward self as well as microbial non-self-antigens, and this resulted in vivo in transplantation tolerance and protection from inflammatory allergy. Talpha1 is produced in vivo by cleavage of prothymosin alpha in diverse mammalian tissues. Our data qualify Talpha1 as an endogenous regulator of immune homeostasis and suggest that instructive immunotherapy with Talpha1, via DCs and tryptophan catabolism, could be at work to control inflammation, immunity, and tolerance in a variety of clinical settings.

[1]  A. Prescott,et al.  Proximal effects of Toll-like receptor activation in dendritic cells. , 2007, Current opinion in immunology.

[2]  R. Lechler,et al.  CD4+CD25+ regulatory T-cell therapy for allergy, autoimmune disease and transplant rejection. , 2006, Inflammation & allergy drug targets.

[3]  G. Rasi,et al.  Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. , 2006, Blood.

[4]  Wanjun Chen.  Dendritic cells and (CD4+)CD25+ T regulatory cells: crosstalk between two professionals in immunity versus tolerance. , 2006, Frontiers in bioscience : a journal and virtual library.

[5]  Katia Perruccio,et al.  Toward the identification of a tolerogenic signature in IDO-competent dendritic cells. , 2006, Blood.

[6]  P. Puccetti,et al.  Immunity and Tolerance to Aspergillus Involve Functionally Distinct Regulatory T Cells and Tryptophan Catabolism1 , 2006, The Journal of Immunology.

[7]  P. Puccetti,et al.  Toll‐like receptor 9‐mediated induction of the immunosuppressive pathway of tryptophan catabolism , 2006, European journal of immunology.

[8]  H. Oberg,et al.  Regulation of regulatory T cells: role of dendritic cells and toll-like receptors. , 2006, Critical reviews in immunology.

[9]  M. Smyth,et al.  Cross-talk between dendritic cells and natural killer cells in viral infection. , 2005, Molecular immunology.

[10]  J. Koziol,et al.  Genetic dissection of innate immunity to infection: the mouse cytomegalovirus model. , 2005, Current opinion in immunology.

[11]  R. Khanna,et al.  Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. , 2004, The Lancet. Infectious diseases.

[12]  Angela Panoskaltsis-Mortari,et al.  Human Plasmacytoid Dendritic Cells Activated by CpG Oligodeoxynucleotides Induce the Generation of CD4+CD25+ Regulatory T Cells1 , 2004, The Journal of Immunology.

[13]  D. Schwartz,et al.  Toll-like receptors in the pathogenesis of human disease , 2004, Nature Immunology.

[14]  D. Munn,et al.  Ido expression by dendritic cells: tolerance and tryptophan catabolism , 2004, Nature Reviews Immunology.

[15]  G. Rasi,et al.  Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. , 2004, Blood.

[16]  A. Goldstein,et al.  Thymosins: chemistry and biological properties in health and disease , 2004, Expert opinion on biological therapy.

[17]  S. Sakaguchi.  Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. , 2004, Annual review of immunology.

[18]  Michel C Nussenzweig,et al.  Tolerogenic dendritic cells. , 2003, Annual review of immunology.

[19]  E. Burchielli,et al.  From bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 22, 2013. For personal use only. , 2002 .

[20]  U. Grohmann,et al.  Tolerance, DCs and tryptophan: much ado about IDO. , 2003, Trends in immunology.

[21]  D. Umetsu,et al.  Asthma: an epidemic of dysregulated immunity , 2002, Nature Immunology.

[22]  Charles A. Janeway,et al.  Decoding the Patterns of Self and Nonself by the Innate Immune System , 2002, Science.

[23]  C. Montagnoli,et al.  Dendritic Cells Transport Conidia and Hyphae of Aspergillus fumigatus from the Airways to the Draining Lymph Nodes and Initiate Disparate Th Responses to the Fungus1 , 2002, The Journal of Immunology.

[24]  A. Sodhi,et al.  Involvement of mitogen-activated protein kinases in the signal transduction pathway of bone marrow-derived macrophage activation in response to in vitro treatment with thymosin alpha 1. , 2002, International immunopharmacology.

[25]  S. Akira,et al.  Toll-like receptors control activation of adaptive immune responses , 2001, Nature Immunology.

[26]  S. Akira,et al.  Toll-like receptors: critical proteins linking innate and acquired immunity , 2001, Nature Immunology.

[27]  William R. Kirkpatrick,et al.  Invasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes , 2000, Medicine.

[28]  A. Guha,et al.  Purification and biological activity of thymosin, a hormone of the thymus gland. , 1972, Proceedings of the National Academy of Sciences of the United States of America.